Prophylactic Properties of Carrot Juice in Patients With High-Risk Colorectal Polyps

Launched by ODENSE UNIVERSITY HOSPITAL · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating whether drinking carrot juice can help prevent colorectal cancer in patients who have had high-risk polyps removed from their large intestine. The study specifically looks at the effects of certain natural compounds found in carrots, called polyacetylenes, to see if they can stop these polyps from turning into cancer. Participants in the trial will be asked to drink 100 ml of carrot juice daily for one year after their surgery and keep a simple diary of their experiences.

To be eligible for this trial, participants must have had surgery to remove adenomas (a type of polyp) that are larger than 20 mm. They should also be able to understand the study's instructions and agree to follow the treatment plan. However, certain individuals, such as those with specific health conditions or allergies, may not be able to participate. Throughout the trial, researchers will compare the effects of the carrot juice with a placebo (a juice without active ingredients) to determine if the carrot juice truly helps reduce the risk of cancer growth. This study is currently recruiting participants, and everyone aged 65 to 74 is welcome to apply.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Any type of resection for adenomas larger than 20 mm in size (endoscopically evaluated).
• • 2. Acceptance of the treatment and follow-up program.
• • 3. Capability to understand and follow the instructions.
• Exclusion Criteria:
• • 1. Patients allocated to "high-risk" group because of many small polyps (\>4).
• • 2. Pregnancy.
• • 3. Known relevant allergies.
• • 4. Chronic consumption of COX (cyclooxygenase) inhibitors (Aspirin, Celecoxib, Ibuprofen, Diclofenac, Ketoprofen, Ketorolac, Indometacin, Naproxen, Piroxicam) or immunosuppressive agents (Methotrexate, Azathioprine or glucocorticoids).
• • 5. Severe comorbidity NYHA III-IV.
• • 6. Lynch syndrome.